Language
CN
EN
Product pipeline
Product ID
Product
Discovery Preclinic IND Clinical
Features

DIFF-flu

Trivalent intranasal influenza vaccine for humans
FIC; M2 gene modification achieves balance between attenuation for safety and robust immunogenicity for efficacy

DIFF-DIVA H9

Inactivated avian influenza DIVA vaccine
FIC; Versatile platform applicable to H5 and H7 avian influenza vaccines with built-in DIVA capability

DIFF-H9N2

Live attenuated avian influenza vaccine
FIC; Needle-free spray / intranasal / eye-drop delivery reduces labor costs

DIFF-Rab

VSV-vectored rabies vaccine for companion animals
BIC; Adjuvant-free, eliminating stress and adjuvant-related side effects

DIFF-OV 001

Oncolytic virus therapies for animals
Me-better; Complete tumor eradication in mouse model with safe, potent VSV oncolytic virus
  • Mucosal Immunization

    Mucosal immunization methods can effectively produce mucosal antibodies, block pathogens from invading the body's first line of defense, prevent infections, and reduce population transmission

    The mucosal immune vaccine developed by DIFF Biotech has stronger efficacy against mutant strains and broad-spectrum preventive effects

    Vaccine administration via nasal spray is a non-invasive method that is more suitable for promotion and large-scale vaccination compared to traditional injection

  • Oncolytic Virus
    Oncolytic virotherapy employs genetically engineered viruses to selectively infect and kill tumor cells while sparing healthy cells, offering unique advantages. It not only directly lyses tumor cells but also releases tumor antigens to activate the host immune system, establishing immune memory against tumors. Additionally, oncolytic viruses can carry gene-editing tools or immunomodulatory molecules to enhance anticancer efficacy. With strong targeting ability, low toxicity, and the potential to combine with radiotherapy, chemotherapy, or immune checkpoint inhibitors, this therapy significantly improves treatment outcomes.
  • Pseudovirus

    Pseudoviruses are typically constructed by grafting the envelope proteins of the target virus onto the scaffold of a specific vector virus, forming virus particles that can be either replication-competent or replication-defective, with various preventive and therapeutic applications

    A more stable viral particle structure compared to traditional inactivated vaccines can induce higher levels of neutralizing antibodies

    It has the advantages of attenuated live vaccines and live vector vaccines, with higher safety and faster generation of effective immune responses

    For highly pathogenic pathogens, the dummy disease platform technology significantly reduces the biosafety level, facilitating production and preparation

Nasal spray attenuated influenza trivalent vaccine

Our company's nasal spray trivalent attenuated influenza vaccine is the first domestically produced human nasal spray influenza vaccine with independent intellectual property rights. This product adopts the world's first M2 gene modified attenuated technology, which has disruptive technological innovation significance and fills the gap in China's attenuated vaccine technology field. Currently, we have obtained multiple domestic and international invention patent authorizations. Our nasal spray influenza vaccine is a attenuated strain of influenza with limited replication ability, which does not rely on low-temperature conditions for replication and avoids the risk of viral mutation infection in cold air environments. The non clinical trial results indicate that the influenza vaccine developed by our company has a shorter detoxification time, lower viral load in animal tissues, fewer side effects, and higher safety and stability after intranasal administration. At the same time, it can induce multi-level immune protection including mucosal immunity, humoral immunity, and cellular immunity, covering four different subtypes of influenza A and B, with stronger protective effect, especially against heterologous influenza viruses. In addition, the production of vaccines can adopt mature chicken embryo production technology, which also brings great convenience to production practice. Our nasal spray influenza vaccine is benchmarked against the global multinational company AstraZeneca's marketed nasal spray influenza vaccine product Flumist, breaking the limitation of insufficient protection against mutant strains in current marketed influenza vaccines. We have also made new breakthroughs in broad-spectrum and safety, and are expected to solve the industry pain points of insufficient protection against seasonal influenza vaccines that require frequent research and development but insufficient mass production. The needle free design of nasal spray vaccination also provides an alternative solution for groups who are afraid of injections, especially for children. The needle free design can improve the feeling and willingness of vaccination.